Titan Medical Inc.

Titan Medical Inc.

October 21, 2010 07:00 ET

Titan Medical Inc. Appoints Three Additional Urology Veterans to Its Medical Advisory Board

TORONTO, ONTARIO--(Marketwire - Oct. 21, 2010) - Titan Medical Inc. ("the Company") (TSX VENTURE:TMD) announced today the appointment of David M. Albala, M.D., Louis Eichel, M.D. and Po N. Lam, M.D. to the Company's Medical Advisory Board.

Craig Leon, Chairman and CEO of Titan Medical, commented, "Urology is one of the first target markets for which we are going to seek approval of Amadeus, and we are extremely pleased to welcome three experts in the field to our team. The combined clinical and educational experience of Drs. Albala, Eichel and Lam equips us with cutting edge scientific knowledge of robotic urologic surgery and positions us for making further progress with developing our technology."

David M. Albala, M.D.

Dr. Albala, currently Chief of Urology at Crouse Hospital in Syracuse, New York and Medical Director for Associated Medical Professionals, brings to Titan Medical over 20 years of laparoscopic and robotic urological surgery expertise recognized worldwide.

During his distinguished medical career, Dr. Albala was an endourology fellow at Washington University Medical Center under the direction of Ralph V. Clayman. He also practiced at Loyola University Medical Center in Chicago where he became Professor in Urology and Radiology. Later on, he became a tenured Professor at Duke University Medical Center in North Carolina where he was Co-Director of the Endourology fellowship and Director for the Center of Minimally Invasive and Robotic Urological Surgery. Dr. Albala's additional clinical interests include minimally invasive treatment of benign prostatic hypertrophy (BPH) and the use of fibrin sealants in surgery.

Dr. Albala received his medical school training at Michigan State University and completed his surgical residency at the Dartmouth-Hitchcock Medical Center. He has been a Visiting Professor at numerous institutions across the world, has done operative demonstrations in over 32 countries and 23 states, and trained 16 fellows in endourology and advanced robotic surgery. He has over 180 journal publications and has authored three textbooks in endourology and one in general urology. Dr. Albala serves on the editorial board for the Journal of Robotic Surgery, Journal of Endourology, Current Opinions in Urology and Urology Index and Reviews. He is also a reviewer for eight surgical journals.

Louis Eichel, M.D.

Dr. Eichel has an extensive background in researching the clinical aspects of surgical robotics and surgical simulation. He currently practices in Rochester, NY and is a Clinical Assistant Professor of Urology at the University of Rochester.

Previously, he has served as a faculty member at several courses on advanced laparoscopic and robotic urologic surgery and has published numerous articles, book chapters, and teaching videos in these areas. He is a recipient of the Pfizer Scholars in Urology Award and also serves as a reviewer for "Urology" and the "Journal of Endourology," and several other journals pertaining to minimally invasive surgery. Dr. Eichel is a member of The American Urological Association, The Endourology Society, and The Society of Laparoscopic Surgeons, and The Minimally Invasive Robotic Association.

Dr. Louis Eichel is a graduate of the University of Rochester School of Medicine and Dentistry where he also completed his residency. Additionally, he completed two years of fellowship training in Laparoscopy, Endourology, and Robotic Surgery at the University of California, Irvine under the direction of Dr. Ralph V. Clayman, Elspeth M. McDougall, and Dr. Thomas E. Ahlering.

Po N. Lam, M.D.

Dr. Lam specializes in oncologic robotic and laparoscopic surgery in Central New York and has performed over 500 robotic surgeries since 2006. He has also served as the director of robotic surgery at Community General Hospital in Syracuse since 2008.

He graduated from medical school at the University of Texas Southwestern Medical Center in Dallas with a major in Latin and Biochemistry and completed his Urology residency at SUNY-Buffalo. Dr. Lam continued a Fellowship in Endourology at the University of Oklahoma Medical Center, where he developed laparoscopic and robotic skills. He has several published papers in the peer-reviewed journals and presented at national and international conferences.

About Titan Medical Inc.

Titan Medical Inc. is a Canadian public company (TSX VENTURE:TMD) focused on the development and commercialization of robotic surgical technologies. The Company is currently developing Amadeus, a next generation 4-armed robotic surgical system, with the objective of enabling surgeons to remotely manipulate surgical instruments. Robotic surgery has developed over the past 10 years into a proven and growing method of treatment. The current global robotic surgical market size is approximately $1 billion and is estimated to grow to $5 billion by 2015 with potential for placement of 6,000 robotic surgical systems. The Company is researching and developing innovative technologies to empower surgeons to use robots in the operating room of the future. For more information, visit the Company's website at www.titanmedicalinc.com.

Forward Looking Statements

This news release contains "forward-looking statements" which reflect the current expectations of management of the Company's future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of the Company's Annual Information Form dated April 9, 2010 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information